EQS-News: Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb

Hamburg, Germany, 04 March 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced another major accomplishment in its long-standing neuroscience collaboration with Bristol Myers Squibb (NYSE: BMY). The latest scientific achievement in the partnership has triggered a research payment of US$20 m to Evotec, enabling further development of a promising pre-clinical programme in neurodegeneration.

Since the initiation of their strategic neuroscience collaboration in December 2016, Evotec and Bristol Myers Squibb have been working together to identify disease-modifying treatments for a broad range of neurodegenerative diseases. While currently approved therapies primarily focus on symptom management, this partnership aims to develop transformative treatments that can slow or halt disease progression - addressing a significant unmet medical need.

The collaboration has already yielded strong results, including the in-licensing of EVT8683 (now BMS-986419) by Bristol Myers Squibb in September 2021. In March 2023, the companies reaffirmed their commitment by extending and expanding the collaboration for an additional eight years.

Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, commented:
“This latest achievement further underscores the strength of our collaboration with Bristol Myers Squibb and the impact it has for jointly building a strong pipeline in neurological diseases. Our continued success highlights the unique commitment and reinforces our shared mission to deliver truly innovative treatment options for patients suffering from neurodegenerative diseases. With another high-potential program advancing towards clinical development, we are taking yet another important step in our pursuit of breakthrough therapies.”

About Evotec SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company’s sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.

Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For further information, please contact:

Investor Relations
Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com

Media
Susanne Kreuter 
VP Head of Strategic Marketing 
Susanne.Kreuter@evotec.com